New data for adcetris® (brentuximab vedotin) with immunotherapy combination in hodgkin lymphoma to be featured at 2023 ash annual meeting, and seagen to unveil novel cd30-directed antibody-drug conjugate

Bothell, wash.--(business wire)-- #ash23--seagen inc. (nasdaq: sgen) today announced that 12- and 24-month progression free survival data will be presented for an adcetris® (brentuximab vedotin) and immunotherapy combination in early and advanced stage classical hodgkin lymphoma (chl), respectively. the data will be featured in two oral presentations at the 65th american society of hematology (ash) annual meeting & exposition, taking place december 9-12, 2023 in san diego. the ongoing phase 2 clinic.
SGEN Ratings Summary
SGEN Quant Ranking